Preoperative computed tomography-based tumoral radiomic features prediction for overall survival in resectable non-small cell lung cancer

Objectives The purpose of this study was to evaluate whether preoperative radiomics features could meliorate risk stratification for the overall survival (OS) of non-small cell lung cancer (NSCLC) patients. Methods After rigorous screening, the 208 NSCLC patients without any pre-operative adjuvant therapy were eventually enrolled. We segmented the 3D volume of interest (VOI) based on malignant lesion of computed tomography (CT) imaging and extracted 1542 radiomics features. Interclass correlation coefficients (ICC) and LASSO Cox regression analysis were utilized to perform feature selection and radiomics model building. In the model evaluation phase, we carried out stratified analysis, receiver operating characteristic (ROC) curve, concordance index (C-index), and decision curve analysis (DCA). In addition, integrating the clinicopathological trait and radiomics score, we developed a nomogram to predict the OS at 1 year, 2 years, and 3 years, respectively. Results Six radiomics features, including gradient_glcm_InverseVariance, logarithm_firstorder_Median, logarithm_firstorder_RobustMeanAbsoluteDeviation, square_gldm_LargeDependenceEmphasis, wavelet_HLL_firstorder_Kurtosis, and wavelet_LLL_firstorder_Maximum, were selected to construct the radiomics signature, whose areas under the curve (AUCs) for 3-year prediction reached 0.857 in the training set (n=146) and 0.871 in the testing set (n=62). The results of multivariate analysis revealed that the radiomics score, radiological sign, and N stage were independent prognostic factors in NSCLC. Moreover, compared with clinical factors and the separate radiomics model, the established nomogram exhibited a better performance in predicting 3-year OS. Conclusions Our radiomics model may provide a promising non-invasive approach for preoperative risk stratification and personalized postoperative surveillance for resectable NSCLC patients.

[1]  Xueyan Zhang,et al.  Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients , 2022, Biomarker research.

[2]  L. Guerra,et al.  The “digital biopsy” in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  F. Izzo,et al.  Radiomics textural features by MR imaging to assess clinical outcomes following liver resection in colorectal liver metastases , 2022, La radiologia medica.

[4]  E. Neri,et al.  The Role of Chest CT Radiomics in Diagnosis of Lung Cancer or Tuberculosis: A Pilot Study , 2022, Diagnostics.

[5]  Xiangming Fang,et al.  Comparison of Comprehensive Morphological and Radiomics Features of Subsolid Pulmonary Nodules to Distinguish Minimally Invasive Adenocarcinomas and Invasive Adenocarcinomas in CT Scan , 2022, Frontiers in Oncology.

[6]  Jingyun Shi,et al.  Deep Learning for Prediction of N2 Metastasis and Survival for Clinical Stage I Non-Small Cell Lung Cancer. , 2021, Radiology.

[7]  R. Gillies,et al.  Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images , 2021, Journal for ImmunoTherapy of Cancer.

[8]  Jianbo Gao,et al.  TCGA-TCIA-Based CT Radiomics Study for Noninvasively Predicting Epstein-Barr Virus Status in Gastric Cancer. , 2021, AJR. American journal of roentgenology.

[9]  QUAN LIU,et al.  A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer , 2021, Frontiers in Oncology.

[10]  I. Castiglioni,et al.  Radiomics and gene expression profile to characterise the disease and predict outcome in patients with lung cancer , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  R. Gillies,et al.  Application of Radiomics and Artificial Intelligence for Lung Cancer Precision Medicine. , 2021, Cold Spring Harbor perspectives in medicine.

[12]  Hubing Wu,et al.  Radiomics analysis of [18F]FDG PET/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  R. Boellaard,et al.  Advanced analytics and artificial intelligence in gastrointestinal cancer: a systematic review of radiomics predicting response to treatment , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  R. Gillies,et al.  Non-invasive decision support for NSCLC treatment using PET/CT radiomics , 2020, Nature Communications.

[15]  M. Zeng,et al.  Histological Subtypes Classification of Lung Cancers on CT Images Using 3D Deep Learning and Radiomics. , 2020, Academic radiology.

[16]  Y. She,et al.  Radiomics nomogram for prediction disease-free survival and adjuvant chemotherapy benefits in patients with resected stage I lung adenocarcinoma , 2020, Translational lung cancer research.

[17]  Y. She,et al.  Radiomics Signature Predicts the Recurrence-Free Survival in Stage I Non-Small-Cell Lung Cancer. , 2020, The Annals of thoracic surgery.

[18]  Georg Langs,et al.  Introduction to Radiomics , 2020, The Journal of Nuclear Medicine.

[19]  Prateek Prasanna,et al.  CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in Stage I, II resectable Non-Small Cell Lung Cancer: a retrospective multi-cohort study for outcome prediction. , 2020, The Lancet. Digital health.

[20]  S. Nie,et al.  A prognostic analysis method for non-small cell lung cancer based on the computed tomography radiomics , 2020, Physics in medicine and biology.

[21]  Bin Zhang,et al.  Association of MRI-derived radiomic biomarker with disease-free survival in patients with early-stage cervical cancer , 2020, Theranostics.

[22]  R. Gillies,et al.  Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Jie Tian,et al.  Radiomic signature: A novel magnetic resonance imaging-based prognostic biomarker in patients with skull base chordoma. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  Xinming Zhao,et al.  Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  P. Pang,et al.  A radiomics model for determining the invasiveness of solitary pulmonary nodules that manifest as part-solid nodules. , 2019, Clinical radiology.

[26]  D. Rubin,et al.  Radiomics and Radiogenomics , 2019, Machine and Deep Learning in Oncology, Medical Physics and Radiology.

[27]  Xiao Li,et al.  Spatial Bayesian modeling of GLCM with application to malignant lesion characterization , 2019, Journal of applied statistics.

[28]  Xiaobo Zhou,et al.  Development of a radiomics nomogram based on the 2D and 3D CT features to predict the survival of non-small cell lung cancer patients , 2018, European Radiology.

[29]  R. Govindan,et al.  Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Beer,et al.  A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer , 2018, EBioMedicine.

[31]  Prateek Prasanna,et al.  Radiomics and radiogenomics in lung cancer: A review for the clinician. , 2018, Lung cancer.

[32]  M. Diehn,et al.  Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer , 2017, JAMA oncology.

[33]  Andriy Fedorov,et al.  Computational Radiomics System to Decode the Radiographic Phenotype. , 2017, Cancer research.

[34]  J. E. van Timmeren,et al.  Influence of gray level discretization on radiomic feature stability for different CT scanners, tube currents and slice thicknesses: a comprehensive phantom study , 2017, Acta oncologica.

[35]  P. Brennan,et al.  Lung Cancer Risk Prediction Model Incorporating Lung Function: Development and Validation in the UK Biobank Prospective Cohort Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Yanqi Huang,et al.  Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. , 2016, Radiology.

[37]  Paul Kinahan,et al.  Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.

[38]  Baolan Li,et al.  Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer , 2015, Scientific Reports.

[39]  R. Rami-Porta,et al.  Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities. , 2015, Translational lung cancer research.

[40]  Benjamin R Saville,et al.  Decision curve analysis. , 2015, JAMA.

[41]  J. Hernando Cubero,et al.  Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. , 2015, Translational lung cancer research.

[42]  B. Pasche,et al.  Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. , 2014, JAMA.

[43]  Milan Sonka,et al.  3D Slicer as an image computing platform for the Quantitative Imaging Network. , 2012, Magnetic resonance imaging.

[44]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  Paul J. Perry,et al.  A Review for the Clinician , 2002 .

[46]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[47]  Markus Voelter,et al.  State of the Art , 1997, Pediatric Research.